TrialAdvances in respiratory medicine2024

RNA Polymerase Inhibitor Enisamium for Treatment of Moderate COVID-19 Patients: A Randomized, Placebo-Controlled, Multicenter, Double-Blind Phase 3 Clinical Trial.

Olga Holubovska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.